Placeholder Banner

BIO Applauds USDA-FDA Agreement to Improve Coordination

January 30, 2018

Specifically, the agreement references the recently released Agricultural and Rural Prosperity Task Force’s Report and says “USDA and FDA are committed to modernizing the Coordinated Framework for the Regulation of Biotechnology and the U.S. agricultural biotechnology regulatory system to develop efficient, science-based regulatory practices for products of biotechnology by working in partnership with other federal agencies on the corresponding National Strategy for Modernizing the Regulatory Systems for Biotechnology Products.”

“BIO applauds the agreement and supports the broad recommendation to enhance coordination between the agencies governing the use of products using agricultural biotechnology,” said Dana O'Brien, BIO’s Executive Vice President for Food & Agriculture. “BIO has long supported a more harmonized Coordinated Framework for science-based regulation, especially in regard to the treatment of future products such as gene edited innovations.”

O’Brien echoed many of the proposals contained in the Task Force report and the National Strategy and said BIO looks forward to engaging with the Administration on implementation.

“We need national policies that recognize the importance of science and technology and encourage continued investment,” O’Brien said. “This agreement is another step forward towards a system that promotes ag innovation, economic growth, competitiveness and job creation in America’s thriving biotechnology sector.”

Discover More
Today, the Biotechnology Innovation Organization (BIO) submitted its comments in response to the U.S. Department of Agriculture’s (UDSA) Solicitation of Input from Stakeholders on Agricultural Innovations, part of the Department’s Agriculture…
Washington, D.C. (July 29, 2020) – The Food and Agriculture Section of the Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Board leadership. Sylvia Wulf, CEO of AquaBounty Technologies, Inc., and Brian…
Says biopharma researchers and scientists stand ready to support real solutions that will address patient drug costs, continue lifesaving science Dr. Michelle McMurry-Heath, the president and CEO of the Biotechnology Innovation Organization (BIO),…